Rajendran Anbalagan - 06 Nov 2025 Form 4 Insider Report for Lifevantage Corp (LFVN)

Reporting relationship: Director
Issuer ticker: LFVN
Reported as of: 06 Nov 2025
Net transaction value: +$105,001
SEC form: 4
Accepted by SEC: 10 Nov 2025, 19:15:14 UTC
Prior SEC filing: 12 Nov 2024
Source filing: View source filing
Reporting owner signature: /s/ Alissa Neufeld, Power of Attorney for Rajendran Anbalagan

Key filing fact

Rajendran Anbalagan filed Form 4 for Lifevantage Corp (LFVN) on 10 Nov 2025.

Key facts

This page summarizes Rajendran Anbalagan's Form 4 filing for Lifevantage Corp (LFVN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 10 Nov 2025, 19:15.

Change

Previous filing in this sequence was filed on 12 Nov 2024.
Current net transaction value: +$105,001.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002033756 Primary reporting owner

Anbalagan Rajendran

Relationship: Director
Address: 3300 TRIUMPH BLVD, SUITE 700, LEHI
Signature: /s/ Alissa Neufeld, Power of Attorney for Rajendran Anbalagan
Signature date: 10 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LFVN transaction

Common Stock

Award

Transaction value: $105,001
Shares: +13,531
Change %: +129%
Price: $7.76
Shares after: 23,999
Date: 06 Nov 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares were granted to the reporting person pursuant to the issuer's outside director compensation program and will vest in a single installment on November 6, 2026, subject to the reporting person's continuous service to the issuer through such date.

Footnote F2

The price reported in Column 4 is equal to the weighted average closing price of the issuer's common stock for the ten trading days ending the day before the date of the grant.